Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Advanced Research in Glaucoma: Treatment and Postoperative Approaches
share announcement

Advanced Research in Glaucoma: Treatment and Postoperative Approaches

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 6302

Special Issue Editor

Dr. Kazuyuki Hirooka

E-Mail Website
Guest Editor
Department of Ophthalmology and Visual Science, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima 734-8551, Japan
Interests: glaucoma; neuroprotection; aldosterone; MIGS; glaucoma surgery

Special Issue Information

Dear Colleagues,

Treatment goals for glaucoma have focused almost exclusively on lowering intraocular pressure (IOP) using drugs, laser therapy, or surgery. Surgery should be considered whenever medical or laser treatment is unlikely to maintain sight in the glaucomatous eye. This Special Issue of the Journal of Personalized Medicine aims to highlight the current treatment of glaucoma. It is important to investigate both the safety and the efficacy of IOP-lowering medication, laser surgery, or incisional surgery. I am confident that the results of such studies will be beneficial not only for glaucoma patients but also for physicians. The accumulation of these results will improve the quality of life in patients with glaucoma.

Dr. Kazuyuki Hirooka
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • medical treatment 
  • adherence 
  • laser surgery 
  • incisional surgery 
  • minimally invasive glaucoma surgery 
  • long-tube glaucoma drainage devices

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research

2 pages, 162 KiB  
Editorial
Advanced Research in Glaucoma: Treatment and Postoperative Approaches
by Kazuyuki Hirooka
J. Pers. Med. 2023, 13(6), 895; https://doi.org/10.3390/jpm13060895 - 25 May 2023
Viewed by 698
Abstract
The principal proven treatment methods for glaucoma management almost exclusively focus on lowering the intraocular pressure (IOP) [...] Full article
(This article belongs to the Special Issue Advanced Research in Glaucoma: Treatment and Postoperative Approaches)

Research

Jump to: Editorial

9 pages, 3271 KiB  
Communication
“Ab Interno” Surgery of the Schlemm’s Canal in Postuveitic Glaucoma Patients
by Ivan Tanev and Radina Kirkova
J. Pers. Med. 2023, 13(3), 456; https://doi.org/10.3390/jpm13030456 - 28 Feb 2023
Cited by 2 | Viewed by 947
Abstract
Background: Patients with uveitis have a higher risk of developing glaucoma not only because of the disease by itself, but also because of the ongoing corticosteroid therapy. The pathogenesis of uveitic glaucoma is characterized by a complex of biochemical and cellular processes, as [...] Read more.
Background: Patients with uveitis have a higher risk of developing glaucoma not only because of the disease by itself, but also because of the ongoing corticosteroid therapy. The pathogenesis of uveitic glaucoma is characterized by a complex of biochemical and cellular processes, as well as morphological changes in the trabecular meshwork. Treatment of secondary chronic glaucoma is challenging and often requires different approaches and solutions. Purpose: To present the “ab interno” procedure of the Schlemm‘s canal (SC) performed with the help of TrabEx+ (MST, Redmond, WA, USA) in postuveitic glaucoma patients. Methods: The observed group included patients with postuveitic secondary glaucoma, which consisted of 12 pseudophakic patients (12 eyes). Patients are with intraocular pressure higher than 25 mmHg and on maximal local therapy. Due to insufficient conservative control on IOP, surgical solutions are needed. We describe a new, minimally invasive surgical procedure–the technique of the operation, the postoperative results and complications. Results: We present the achieved intraocular pressure (on the first day, 2 weeks, 1 month, 6, 8 12 and 18 months). The morphology of the trabecular area was demonstrated by gonioscopy. The effects of the therapy on the glaucoma progression, was evaluated with perimetry and OCT. Discussion: The following procedure is a minimally invasive procedure and provides good control of intraocular pressure. Aqueous veins in the conjunctiva are significantly preserved compared to conventional filtration trabeculectomy. This potentially modulates the physiological outflow pathways by ablating trabeculum strip the cause of increased outflow resistance-the inner wall of the SC. Conclusion: Removal of the inner wall of the SC, using Trabex+ (MST, Redmond, WA, USA), demonstrates promising results in the selected patients with a minimally invasive nature. Full article
(This article belongs to the Special Issue Advanced Research in Glaucoma: Treatment and Postoperative Approaches)
►▼ Show Figures

Figure 1

7 pages, 539 KiB  
Article
The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients
by Hiromitsu Onoe, Kazuyuki Hirooka, Mikio Nagayama, Hideki Mochizuki, Atsushi Hirota, Katsuyoshi Suzuki, Takeshi Sagara and Yoshiaki Kiuchi
J. Pers. Med. 2022, 12(12), 2057; https://doi.org/10.3390/jpm12122057 - 13 Dec 2022
Cited by 3 | Viewed by 1001
Abstract
We evaluated switching from brinzolamide 1% or brimonidine 0.1% to a fixed-combination of brinzolamide 1% and brimonidine 0.1%, and then determined the efficacy, safety, and satisfaction associated with these changes in glaucoma patients. This prospective, nonrandomized study evaluated a total of 31 enrolled [...] Read more.
We evaluated switching from brinzolamide 1% or brimonidine 0.1% to a fixed-combination of brinzolamide 1% and brimonidine 0.1%, and then determined the efficacy, safety, and satisfaction associated with these changes in glaucoma patients. This prospective, nonrandomized study evaluated a total of 31 enrolled glaucoma patients who underwent treatment with at least brinzolamide 1% or brimonidine 0.1%. Patients were administered a brinzolamide/brimonidine fixed-combination ophthalmic suspension (BBFC) after being switched from their original brinzolamide 1% or brimonidine 0.1% therapy. All other intraocular pressure (IOP)-lowering medications currently being used were continued. IOP, superficial punctate keratopathy (SPK), and conjunctival hyperemia data obtained at baseline and then at 4 and 12 weeks were evaluated. To assess the changes in treatment satisfaction, this study utilized the Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9). There was a significant decrease in the mean baseline IOP from 15.7 ± 4.9 mmHg to 13.6 ± 4.4 (p = 0.001) and 13.5 ± 3.9 mmHg (p = 0.002) at 4 and 12 weeks, respectively. Evaluation of the incidence of conjunctival hyperemia or SPK score showed there were no significant changes noted at any time point. The TSQM-9 score demonstrated there was a significant increase for effectiveness after switching from brinzolamide 1% or brimonidine 0.1% to BBFC. After switching from brinzolamide 1% or brimonidine 0.1% to BBFC, there was a significant decrease in the IOP. Patients were aware of the effectiveness of switching from brinzolamide 1% or brimonidine 0.1% to BBFC. Full article
(This article belongs to the Special Issue Advanced Research in Glaucoma: Treatment and Postoperative Approaches)
►▼ Show Figures

Figure 1

8 pages, 726 KiB  
Article
Real-World Analysis of the Aging Effects on Visual Field Reliability Indices in Central 10-2 Tests
by Tomoki Shirakami, Tetsuro Omura, Hiroki Fukuda, Ryo Asaoka and Masaki Tanito
J. Pers. Med. 2022, 12(10), 1600; https://doi.org/10.3390/jpm12101600 - 28 Sep 2022
Cited by 2 | Viewed by 1157
Abstract
We investigated the influence of aging on the reliability indices of visual field (VF) testing using a large dataset of central 10-2 program tests, including 6674 VF tests, which consisted of 1782 eyes of 1094 Japanese subjects (the mean age ± standard deviation [...] Read more.
We investigated the influence of aging on the reliability indices of visual field (VF) testing using a large dataset of central 10-2 program tests, including 6674 VF tests, which consisted of 1782 eyes of 1094 Japanese subjects (the mean age ± standard deviation was 66.6 ± 14.1 years). All of the combinations for each parameter, except for the pairs between age and fixation losses (FLs) or false positives (FPs) and between pattern standard deviation (PSD) and FPs, had significant correlations (p < 0.0001). Among the reliability indices, the false negatives (FNs) had the strongest correlation against age (the correlation coefficient was ρ = 0.21). Each reliability index changes differently with aging. The FLs were the highest in the first 10 s and remained constant after 20 s. The FNs remained constant for 60 s and rose steeply after 70 s. The FPs reached their highest value in 10 s and remained constant after 40 s. In mixed-effect regression analyses in 40-year-old or older subjects, older age was significantly associated with higher FNs (p < 0.0001) but not with FLs (p = 0.9014) and FPs (p = 0.9267). Compared to central 30-2 VF testing, central 10-2 VF tests were associated with smaller FLs (p < 0.0001) and FPs (p < 0.0001). In central 10-2 testing, age-related deterioration was seen in FNs but not in FLs and FPs. Choosing the 10-2 program over the 30-2 program can be effective in reducing the FL, especially in older cases with severe VF loss. This study highlighted the relationships between age and each reliability index in central 10-2 VF testing. Full article
(This article belongs to the Special Issue Advanced Research in Glaucoma: Treatment and Postoperative Approaches)
►▼ Show Figures

Figure 1

9 pages, 3748 KiB  
Article
Nation-Wide Analysis of Glaucoma Medication Prescription in Fiscal Year of 2019 in Japan
by Masaki Tanito
J. Pers. Med. 2022, 12(6), 956; https://doi.org/10.3390/jpm12060956 - 11 Jun 2022
Cited by 6 | Viewed by 1733
Abstract
To report the updated prescription trend of antiglaucoma medications, the dose-based prescription of a glaucoma medication in Japan in the fiscal year 2019 was aggregated by using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open data. [...] Read more.
To report the updated prescription trend of antiglaucoma medications, the dose-based prescription of a glaucoma medication in Japan in the fiscal year 2019 was aggregated by using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) Open data. Of the 100 most frequently prescribed topical medications for outpatients from out-hospital pharmacies, 32 glaucoma medications were identified. This year, 150.8 million ml of glaucoma medications prescribed accounted for 12.3% of the total prescription dose (1.3 billion ml). The dose was the largest with prostaglandin FP2α agonist (PGF2α), followed by the fixed-dose combination (FDC) of β-blocker and carbonic anhydrase inhibitor (β + CAI) and α2-agonist. Prescription doses peaked at 75–79 years old for all medication classes, except for prostaglandin EP2 agonist of that peaked 10 years younger age class than other medications. The prescription dose was larger in women (55.3%) than men (44.7%), single medication formulation (71.2%) than FDC (28.8%), and brand-name (85.2%) than generic (14.8%). By multivariate analysis, prescription doses were affected by roles of the sex (p = 0.0066) and brand-name or generic (p = 0.032), but not by single medication formulation or FDC (p = 0.67); age was the most remarkable parameter for the difference in prescription dose (p < 0.0001). Dose-based anti-glaucoma medication prescription was analyzed using the government-provided most recent database on a national scale. The results provide the up-to-date real-world glaucoma medication prescriptions where the country has the highest aging rate in the world. Full article
(This article belongs to the Special Issue Advanced Research in Glaucoma: Treatment and Postoperative Approaches)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop